2013 Blogging Funding Research 
Both Sides of the Table
JANUARY 26, 2013
Understanding “The Funding Angle” I sit at enough board meetings to hear conflicting advice given to entrepreneurs about how to handle PR and announcements at startups. Is Funding a Worthy Announcement? There are reasons you may delay funding announcement but rarely reasons not to announce. But trust me on this.
Xconomy
JANUARY 7, 2020
When a group of scientists from Amira Pharmaceuticals wanted to start a new biotech after the company’s 2011 acquisition by Bristol-Myers Squibb , Celgene provided seed funding. Eventually Celgene kicked in $35 million more for a research collaboration, an equity stake, and an exclusive option to acquire the startup, PharmAkea Therapeutics.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
JUNE 13, 2019
The new Series B round will give San Francisco-based BlackThorn—a startup spun out of the Scripps Research Institute in 2013—the backing to run human tests of two experimental treatments. One, headed for Phase 2 testing by next year, is being developed for mood or anxiety disorders.
Both Sides of the Table
JUNE 8, 2014
The basic components are obvious: talented founders, great engineers, angel money, venture capital, access to larger corporates (for business, funding & talent), great education / research (for IP breakthroughs) and a sufficient ecosystem of mentors, advisors, executive coaches and mavens. CincyTech today has $28.5
Xconomy
OCTOBER 20, 2016
As Xconomy reported last year, South San Francisco, CA-based BlackThorn was spun out of Scripps Research Institute , which on its website lists the company as one of its 2013 spinouts. It’s emerging from clinical research.”.
Xconomy
OCTOBER 18, 2016
In three years, Vertex went from having a billion-dollar hepatitis C business to zero—abandoning the research completely. Called sofosbuvir (Sovaldi), the drug won FDA approval in December 2013. Telaprevir’s sales cratered, and Vertex axed 15 percent of its workforce in October 2013. Then it exited HCV research entirely.
Xconomy
AUGUST 12, 2016
Koch Institute for Integrative Cancer Research founding director Tyler Jacks has spent decades making important contributions in cancer research, but until forming Cambridge, MA-based Dragonfly Therapeutics, he’d never spun a startup out of his own lab at MIT. —David H.
Expert insights. Personalized for you.
355 
Let's personalize your content